A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00480688

Enrollment

Registered

2007-05-31

Start date

2001-11-30

Completion date

2002-05-31

Last updated

2007-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keywords

TB, BCG

Brief summary

To assess the immunogenicity of M. bovis BCG, given intrademally in the standard dose used in clinical practice and to measure the development of the immune response in the first six months after administration. M. bovis BCG is a fully licensed vaccine that has been in routine clinical use for the last 50 years. It is the most widely administered vaccine in the world today and has an excellent safety record.

Detailed description

Volunteers for the study will be recruited through advertisements. Each volunteer will have received an information sheet concerning the study and will have agreed to participate in writing. Volunteers will be given at least 48 hours between reading the information leaflet and agreeing to participate. Female volunteers will have a pregnancy test prior to enrollment. Volunteers will give signed consent for their GP's to be notified about their participation in the trial. The GP will be faxed a letter on the day of screening and asked to reply if they know of a reason why the volunteer should not take part. The signed consent form will also be faxed with the letter.

Interventions

BIOLOGICALBCG

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adult aged 18-65 years. * Normal medical history and physical examination. * Normal urine dipstick, blood count, liver enzymes, and creatinine.

Exclusion criteria

* Exposure to TB/BCG vaccination at any point. Previous residence in a TB endemic area. * Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy,immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder,liver disease, renal disease, gastrointestinal disease, neurological illness, psychiatric disorder, drug or alcohol abuse. * Oral or systemic steroid medication or the use of immunosuppressive agents. * Positive HIV or core HBV antibody test. * Positive Heaf test * Positive ANA or serum anti-DNA antibody. * Confirmed pregnancy

Design outcomes

Primary

Measure	Time frame
Induction of T cell responses	6 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026